CSS LLC’s Gyre Therapeutics GYRE Stock Holding History

CSS LLC’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,821	Closed	-$59K	–	1152
2022 Q1	$59K	Hold	11,821	–	–	﹤0.01%	994
2021 Q4	$81K	Buy	11,821 +7,348	+164%	+$126K	﹤0.01%	1044
2021 Q3	$138K	Buy	+4,473	New	+$147K	0.01%	933

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

CSS LLC's GYRE Position: Q2 2022 in Review

CSS LLC sold out of Gyre Therapeutics (GYRE) in Q2 2022, closing a stake of 11,821 shares — an estimated $59K sold.

CSS LLC first reported a position in GYRE in Q3 2021 and held it in 3 quarters. The position peaked at $138K in Q3 2021. 41 funds tracked by Wall St. Rank hold GYRE as of Q2 2022.

CSS LLC reported no remaining Gyre Therapeutics position as of Q2 2022 after selling out during the quarter.
CSS LLC sold 11,821 Gyre Therapeutics shares in Q2 2022, an estimated $59K.
CSS LLC first reported a position in Gyre Therapeutics in Q3 2021 and held it in 3 quarters.
CSS LLC's Gyre Therapeutics position peaked at $138K in Q3 2021.
41 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2022.

Based on CSS LLC's 13F filing for Q2 2022, filed 15 Aug 2022.